Ranking of therapeutic regimens for hormone receptor-positive, HER2-negative, metastatic breast cancer (MBC) using information theoretic network meta-analysis.

2050Background: Hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) is treated with targeted therapy, hormone therapy, chemotherapy, or combinations of these modal...